Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives $13.86 Average PT from Analysts

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have earned an average recommendation of “Hold” from the nine brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $13.8571.

BCYC has been the subject of several research analyst reports. Citigroup reiterated a “market outperform” rating on shares of Bicycle Therapeutics in a report on Wednesday, June 3rd. Wall Street Zen upgraded shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Needham & Company LLC cut their price objective on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Wednesday, July 8th.

Insider Activity at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 5,905 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $4.27, for a total value of $25,214.35. Following the sale, the chief executive officer directly owned 605,408 shares in the company, valued at $2,585,092.16. The trade was a 0.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 9,977 shares of company stock valued at $42,702 in the last 90 days. Insiders own 22.00% of the company’s stock.

Institutional Investors Weigh In On Bicycle Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of BCYC. Clearstead Advisors LLC lifted its stake in Bicycle Therapeutics by 234.2% in the 4th quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock valued at $33,000 after acquiring an additional 3,262 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Bicycle Therapeutics by 512.9% during the 2nd quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock worth $33,000 after acquiring an additional 6,447 shares in the last quarter. Pinnacle Wealth Management Advisory Group LLC bought a new position in shares of Bicycle Therapeutics during the 4th quarter worth approximately $71,000. Ausdal Financial Partners Inc. acquired a new stake in shares of Bicycle Therapeutics in the second quarter valued at approximately $70,000. Finally, Vontobel Holding Ltd. acquired a new stake in shares of Bicycle Therapeutics in the fourth quarter valued at approximately $71,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Price Performance

NASDAQ:BCYC opened at $4.30 on Wednesday. The business’s 50-day simple moving average is $4.16 and its 200-day simple moving average is $4.55. Bicycle Therapeutics has a fifty-two week low of $3.74 and a fifty-two week high of $9.16. The stock has a market capitalization of $300.96 million, a PE ratio of -1.58 and a beta of 1.54.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.14). The business had revenue of $0.63 million for the quarter, compared to the consensus estimate of $4.22 million. Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%. On average, research analysts expect that Bicycle Therapeutics will post -2.26 earnings per share for the current year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.